Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.98 |
| ▸ | ABCC1 | P33527 | 4/20 | 0.98 |
| ▸ | ABCC2 | Q92887 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.98 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.98 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.98 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.98 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verlukast SCHEMBL156454 | 1.00 | CYSLTR1 (0.98) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Mk-571 SCHEMBL30509651 | 0.99 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Mk-571 SCHEMBL9231584 | 0.99 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Verlukast SCHEMBL37247 | 0.99 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Verlukast SCHEMBL37246 | 0.99 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Verlukast SCHEMBL2729252 | 0.99 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| Dimethylcarbate SCHEMBL9327878 | 0.94 | CYSLTR1 (0.90) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| SCHEMBL17833480 | 0.93 | CYSLTR1 (0.89) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| SCHEMBL9267947 | 0.92 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 | |
| SCHEMBL9265732 | 0.92 | CYSLTR1 (1.00) | CYSLTR1ABCC1ABCC2MEN1ABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | claimed |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2024-02-08 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| CN-109419799-B | A method for increasing the bioavailability of silibinin | 澳门科技大学 | 2022-12-06 | — | — | CN | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
| WO-2022034529-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| US-20220008400-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2022-01-13 | — | — | US | disclosed |
| EP-3763366-A1 | ROFLUMILAST N-OXIDE FOR USE IN TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION | Incozen Therapeutics Pvt. Ltd. (IN) | 2021-01-13 | — | — | EP | disclosed |
| EP-2948148-B1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | INCOZEN THERAPEUTICS PVT LTD (IN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2005115467-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115466-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115462-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115465-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| WO-2005115464-A1 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS | ALMIRALL PRODESFARMA S.A. (ES) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | ESCARDO JORDI G | 2005-12-01 | — | — | US | disclosed |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | GRAS ESCARDO JORDI | 2005-12-01 | — | — | US | disclosed |
| US-5428171-A | Leukotrienes antagonist; antiasthmatic, antiallergic, anti-inflammatory and cytoprotective agent | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-4851409-A | LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE | MERCK FROSST CANADA INC. (CA) | 1989-07-25 | — | — | US | disclosed |
| EP-0233763-A2 | 2-Substituted quinoline dioic acids | MERCK FROSST CANADA INC. (CA) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008400-A1 | METHODS OF TREATING AUTOIMMUNE, RESPIRATORY AND INFLAMMATORY DISORDERS BY INHALATION OF ROFLUMILAST N-OXIDE | NOS3, NOS2, NOS1 | CYSLTR1 23/4885ABCC1 3208/4885ABCC2 4161/4885 |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | CYSLTR1 2201/4885ABCC1 254/4885ABCC2 168/4885 |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | CYSLTR1 2201/4885ABCC1 254/4885ABCC2 168/4885 |
| US-20050267135-A1 | Combinations comprising antimuscarinic agents and PDE4 inhibitors | CHRM3, PDE4A, CHRM4 | CYSLTR1 197/4885ABCC1 1464/4885ABCC2 2010/4885 |
| US-20050267078-A1 | Combinations comprising antimuscarinic agents and beta-adrenergic agonists | ADRB2, ADRB3, CHRM3 | CYSLTR1 92/4885ABCC1 1053/4885ABCC2 919/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | CYSLTR1 2201/4885ABCC1 254/4885ABCC2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.